Surgical management of high risk prostate cancer: The Mayo Clinic experience

Cooperberg, 2003, Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE), J Urol, 170, S21, 10.1097/01.ju.0000095025.03331.c6 D'Amico, 1998, Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer, JAMA, 80, 969, 10.1001/jama.280.11.969 Kane, 2007, Changing nature of high risk patients undergoing radical prostatectomy, J Urol, 177, 113, 10.1016/j.juro.2006.08.057 Meng, 2005, Treatment of patients with high risk localized prostate cancer: results form cancer of the prostate strategic urological research endeavor (CaPSURE), J Urol, 173, 1557, 10.1097/01.ju.0000154610.81916.81 Ward, 2005, Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome, BJU Int, 95, 751, 10.1111/j.1464-410X.2005.05394.x Meltzer, 2001, Patterns of prostate cancer treatment by clinical stage and age, Am J Public Heath, 91, 126, 10.2105/AJPH.91.1.126 Zincke, 1986, Bilateral pelvic lymphadenectomy and radical prostatectomy for clinical stage C prostate cancer: Role of adjuvant treatment for residual cancer and in disease progression, J Urol, 135, 1199, 10.1016/S0022-5347(17)46034-4 Schenk, 2006, Surgical management of clinical T3 (cT3) and node positive adenocarcinoma of the prostate, 246 Scardino, 2005, Update: NCCN prostate cancer clinical practice guidelines, J Natl Compr Canc Netw, 3, S29 Isaacs, 1989, Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats, Cancer Res, 49, 6290 Sokoloff, 2004, Adjunctive therapy for men with high risk localized and locally advanced prostate cancer: Targeting disseminated tumor cells, J Urol, 172, 2539, 10.1097/01.ju.0000145044.97177.09 Studer UE, Whelan P, Albrecht W, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organization for Research and Treatment of Cancer (EORTC) Trial 20891. J Clin Oncol 24:1868–76. Messing, 2006, Immediate vs. deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy, Lancet Oncol, 7, 472, 10.1016/S1470-2045(06)70700-8 Myers, 2002, Use of adjuvant hormonal therapy with radical prostatectomy in lymph node-positive disease: Rationale and contribution to outcome, 390 Coen, 2002, Radical radiation for localized prostate cancer: Local persistence of disease results in a late wave of metastases, J Clin Oncol, 20, 3199, 10.1200/JCO.2002.01.086 Smith, 2006, Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer, J Clin Oncol, 24, 4448, 10.1200/JCO.2006.06.2497 Blute, 2001, Use of Gleason score, prostate specific antigen, seminal vesicle, and margin status to predict biochemical failure after radical prostatectomy, J Urol, 165, 119, 10.1097/00005392-200101000-00030 Thompson, 2007, Is the GPSM scoring algorithm for prostate cancer patients valid in the contemporary era?, J Urol, 178, 459, 10.1016/j.juro.2007.03.124 Konety, 2004, Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a Phase I/II study, J Urol, 171, 709, 10.1097/01.ju.0000108122.36893.5a